Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the discovery, development and ...

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation (“Orion”) and Abilita Therapeutics ...

Orion Corporation (“Orion”) and Abilita Therapeutics (“Abilita”) announced today that they have entered into a research collaboration and option to license agreement to develop innovative antibody ...

Orion Corporation (“Orion”) and Abilita Therapeutics (“Abilita”) announced today that they have entered into a research collaboration and option to license agreement to develop innovative ...

Orion Corporation ("Orion”) and Abilita Therapeutics ("Abilita”) announced today that they have entered into a research collaboration and option to license agreement to develop innovative antibody ...

18, 2024 /PRNewswire/ -- Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the ...

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation ("Orion") and Abilita Therapeutics ...

18, 2024 /PRNewswire/ -- Abilita Therapeutics, Inc. ("Abilita") today announced a global licensing and multi-target research collaboration with Finnish Orion Corporation ("Orion") focused on the ...